ESC Premium Access

Discussant review: Impact of a single or two dose regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged reductions in LDL-C over 1 year. ORION 1

Topic: Lipids (Epidemiology and Prevention)

Congress Presentation

About the speaker

Professor Philip Barter

University of New South Wales Sydney, Sydney (Australia)
6 presentations
0 follower

17 more presentations in this session

SPYRAL HTN OFF-MED Study

Speaker: Professor M. Boehm (Homburg, DE)

Thumbnail

Discussant review: SPYRAL HTN OFF-MED Study

Speaker: Professor B. Williams (London, GB)

Thumbnail

Panel discussion.

Thumbnail

Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE Trial

Speaker: Professor M. Ezekowitz (Philadelphia, US)

Thumbnail

Discussant review:Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE Trial

Speaker: Professor J. Nielsen (Aarhus, DK)

Thumbnail

Access the full session

Hot Line: Late-Breaking Clinical Trials 2

Speakers: Professor P. Barter, Professor M. Boehm, Professor B. Williams, Professor M. Ezekowitz, Professor J. Nielsen
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by